CytoMed Therapeutics (GDTC) Receivables - Other (2021 - 2025)
CytoMed Therapeutics (GDTC) posted Receivables - Other of $375976.1 for Q4 2025, up 306.44% sequentially from -$182122.0 in Q2 2025, and little changed YoY from $375888.2 in Q4 2024.
CytoMed Therapeutics (GDTC) Receivables - Other (2021 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Receivables - Other for 5 years, with the latest figure at $375976.1 in Q4 2025.
- Quarterly Receivables - Other changed 0.02% year-over-year to $375976.1 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $375976.1 (changed 0.02% YoY) and the FY2025 annual result came in at $372965.0, changed 0.36% from the prior year.
- Receivables - Other rose to $375976.1 in Q4 2025 per GDTC's latest filing, from -$182122.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $1.2 million in Q2 2024 and troughed at -$182122.0 in Q2 2025.
- A 5-year average of $350367.3 and a median of $191928.2 in 2023 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2023 and 2025: Receivables - Other jumped 1715.17% in 2023, then slumped 114.74% in 2025.
- Over 5 years, Receivables - Other stood at $15122.4 in 2021, then soared by 248.52% to $52704.8 in 2022, then jumped by 264.16% to $191928.2 in 2023, then surged by 95.85% to $375888.2 in 2024, then rose by 0.02% to $375976.1 in 2025.
- According to Business Quant data, Receivables - Other over the past three periods registered $375976.1, -$182122.0, and $375888.2 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.91 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.87 Bn | 59.68 Bn | 1.37 Bn |
| 4 | Moderna | 58.18 Bn | 53.04 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.96 Bn | 36.87 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.23 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.79 Bn | 9.40 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.37 Bn | 26.53 Bn | - |
| 10 | CytoMed Therapeutics | 9.97 Mn | 8.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 375,976.05 |
| Dec 31, 2025 | 375,976.05 |
| Jun 30, 2025 | -182,122.00 |
| Jun 30, 2025 | -182,122.00 |
| Dec 31, 2024 | 375,888.22 |
| Dec 31, 2024 | 375,888.22 |
| Jun 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Dec 31, 2023 | 191,928.23 |
| Dec 31, 2023 | 191,928.23 |
| Jun 30, 2023 | 1.03 Mn |
| Jun 30, 2023 | 1.03 Mn |
| Dec 31, 2022 | 52,704.78 |
| Dec 31, 2022 | 52,704.78 |
| Jun 30, 2022 | 56,802.00 |
| Jun 30, 2022 | 56,802.00 |
| Dec 31, 2021 | 15,122.44 |
| Dec 31, 2021 | 15,122.44 |